{"id":1022478,"date":"2026-11-19T06:48:00","date_gmt":"2026-11-19T11:48:00","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/merck-and-isomorphic-labs-enter-strategic-research-collaboration\/"},"modified":"2026-11-19T06:48:00","modified_gmt":"2026-11-19T11:48:00","slug":"merck-and-isomorphic-labs-enter-strategic-research-collaboration","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/merck-and-isomorphic-labs-enter-strategic-research-collaboration\/","title":{"rendered":"Merck and Isomorphic Labs Enter Strategic Research Collaboration"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Merck and Isomorphic Labs Enter Strategic Research Collaboration<\/b><\/p>\n<p>RAHWAY, N.J.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nMerck (NYSE: MRK), known as MSD outside of the United States and Canada, and Isomorphic Labs, an AI-first drug design and development company, today announced a research collaboration that brings together Isomorphic Labs\u2019 AI approach to drug discovery with Merck\u2019s rich proprietary data resources and deep discovery experience.<\/p>\n<p>\nThe companies will collaborate to discover therapeutic small molecule candidates against an oncology target of strategic importance. Isomorphic Labs will perform <i>in silico<\/i> predictions and deliver molecular designs, applying its proprietary drug design engine (IsoDDE) incorporating select high-quality proprietary data sets supplied by Merck for the purpose of this collaboration. Merck will be responsible for preclinical and clinical development, as well as manufacturing and commercialization of any products derived from the collaboration.<\/p>\n<p>\nUnder the terms of the agreement, Isomorphic Labs will receive an upfront payment from Merck and be eligible for payments based on the achievement of specified research, development, regulatory and commercial milestones, as well as tiered royalties on net sales. Isomorphic Labs also receives an option to co-fund development activities in return for elevated royalties.<\/p>\n<p>\n\u201cThe key to successfully leveraging AI\/ML for molecular invention lies in close coordination of wet-lab and dry-lab functions,\u201d said George Addona, senior vice president and head of discovery, preclinical development and translational medicine, Merck Research Laboratories. \u201cBy combining Merck\u2019s substantial internal data capabilities and discovery expertise with Isomorphic Labs\u2019 powerful modeling and compute capabilities, we aim to identify new ways to design and create better candidates faster.\u201d<\/p>\n<p>\n\u201cThrough this collaboration with Merck, we will apply our world-leading drug design engine to unlock significant discovery progress,\u201d said Sarah Skerratt, chief research officer, Isomorphic Labs. \u201cBy leveraging the generative and predictive power of the IsoDDE to address this challenging program, this collaboration highlights our companies\u2019 shared commitment to innovation for the benefit of patient populations with unmet needs.\u201d<\/p>\n<p>\nThe collaboration highlights the transformative power of bringing together advanced AI, unique data sets and established biopharmaceutical leadership to accelerate the advancement of therapeutic candidates, navigating complex biology with unprecedented speed and precision.<\/p>\n<p><b>About Isomorphic Labs<br \/>\n<br \/><\/b>Isomorphic Labs was founded in 2021, to transform drug discovery with the power of artificial intelligence, ushering in a new era of biomedical breakthroughs. Isomorphic Labs is led by CEO Sir Demis Hassabis and President Max Jaderberg. Isomorphic Labs has built a world-leading, modality-agnostic drug design engine (IsoDDE) comprised of foundational AI models. The computational drug-design system provides the predictive fidelity required to navigate novel biological systems with unprecedented accuracy.<\/p>\n<p>\nThe company is continually innovating on model architecture and developing cutting-edge capabilities to advance drug design. Isomorphic Labs is headquartered in London and has office locations in Cambridge, Massachusetts and Lausanne, Switzerland. Isomorphic Labs is advancing a broad and ambitious drug design portfolio through partnered programs and wholly owned internal programs. For more information, go to www.isomorphiclabs.com.<\/p>\n<p><b>About Merck<br \/>\n<br \/><\/b>At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world \u2013 and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.merck.com%2F&amp;esheet=54643554&amp;newsitemid=20261119112890&amp;lan=en-US&amp;anchor=www.merck.com&amp;index=1&amp;md5=8945ddd8c35ff9cacd98fac41da99c4d\">www.merck.com<\/a> and connect with us on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fx.com%2FMerck&amp;esheet=54643554&amp;newsitemid=20261119112890&amp;lan=en-US&amp;anchor=X+%28formerly+Twitter%29&amp;index=2&amp;md5=8d4c072b1fe0714ddab0cf53ec749351\">X (formerly Twitter)<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FMerckInvents%2F&amp;esheet=54643554&amp;newsitemid=20261119112890&amp;lan=en-US&amp;anchor=Facebook&amp;index=3&amp;md5=23d8a44311225dede2530a8554f49160\">Facebook<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fmerck%2F&amp;esheet=54643554&amp;newsitemid=20261119112890&amp;lan=en-US&amp;anchor=Instagram&amp;index=4&amp;md5=f838d6898524f313d7deca00173ada6b\">Instagram<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=54643554&amp;newsitemid=20261119112890&amp;lan=en-US&amp;anchor=YouTube&amp;index=5&amp;md5=de237220c2d6be70991d8d2687a52ea2\">YouTube<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=54643554&amp;newsitemid=20261119112890&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=6&amp;md5=2cd3ffcb51091a41e98f4fe13448fa29\">LinkedIn<\/a>.<\/p>\n<p><b>Forward-Looking statement of Merck &amp; Co., Inc., Rahway, N.J., USA<br \/>\n<br \/><\/b>This news release of Merck &amp; Co., Inc., Rahway, N.J., USA (the \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company\u2019s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.<\/p>\n<p>\nRisks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company\u2019s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company\u2019s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and\/or regulatory actions.<\/p>\n<p>\nThe company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company\u2019s Annual Report on Form 10-K for the year ended December 31, 2025 and the company\u2019s other filings with the Securities and Exchange Commission (SEC) available at the SEC\u2019s Internet site (<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=54643554&amp;newsitemid=20261119112890&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=7&amp;md5=a7ca5d11761417e9d993c3035e0ab7ba\">www.sec.gov<\/a>).<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261119112890r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20261119112890\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20261119112890\/en\/<\/a><\/span><\/p>\n<p>\nMedia Contacts:<\/p>\n<p>Kimberly Petrillo<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:kimberly.petrillo@merck.com\">kimberly.petrillo@merck.com<br \/>\n<\/a><\/p>\n<p>Ned Ehrbar<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:ned.ehrbar@merck.com\">ned.ehrbar@merck.com<br \/>\n<\/a><\/p>\n<p>Investor Contacts:<\/p>\n<p>Peter Dannenbaum<br \/>\n<br \/>(732) 594-1579<\/p>\n<p>Steven Graziano<br \/>\n<br \/>(732) 594-1583<\/p>\n<p><b>KEYWORDS:<\/b> United States North America New Jersey<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Research Technology Health Technology Biotechnology General Health Pharmaceutical Health Science Oncology Artificial Intelligence<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20261119112890\/en\/1106824\/3\/Merck_Logo_Horizontal_Teal-Grey_RGB.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Merck and Isomorphic Labs Enter Strategic Research Collaboration RAHWAY, N.J.&#8211;(BUSINESS WIRE)&#8211; Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Isomorphic Labs, an AI-first drug design and development company, today announced a research collaboration that brings together Isomorphic Labs\u2019 AI approach to drug discovery with Merck\u2019s rich proprietary data resources and deep discovery experience. The companies will collaborate to discover therapeutic small molecule candidates against an oncology target of strategic importance. Isomorphic Labs will perform in silico predictions and deliver molecular designs, applying its proprietary drug design engine (IsoDDE) incorporating select high-quality proprietary data sets supplied by Merck for the purpose of this collaboration. Merck will be responsible for preclinical and clinical development, as well &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/merck-and-isomorphic-labs-enter-strategic-research-collaboration\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Merck and Isomorphic Labs Enter Strategic Research Collaboration&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1022478","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck and Isomorphic Labs Enter Strategic Research Collaboration - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/merck-and-isomorphic-labs-enter-strategic-research-collaboration\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck and Isomorphic Labs Enter Strategic Research Collaboration - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Merck and Isomorphic Labs Enter Strategic Research Collaboration RAHWAY, N.J.&#8211;(BUSINESS WIRE)&#8211; Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Isomorphic Labs, an AI-first drug design and development company, today announced a research collaboration that brings together Isomorphic Labs\u2019 AI approach to drug discovery with Merck\u2019s rich proprietary data resources and deep discovery experience. The companies will collaborate to discover therapeutic small molecule candidates against an oncology target of strategic importance. Isomorphic Labs will perform in silico predictions and deliver molecular designs, applying its proprietary drug design engine (IsoDDE) incorporating select high-quality proprietary data sets supplied by Merck for the purpose of this collaboration. Merck will be responsible for preclinical and clinical development, as well &hellip; Continue reading &quot;Merck and Isomorphic Labs Enter Strategic Research Collaboration&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/merck-and-isomorphic-labs-enter-strategic-research-collaboration\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-19T11:48:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261119112890r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/merck-and-isomorphic-labs-enter-strategic-research-collaboration\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/merck-and-isomorphic-labs-enter-strategic-research-collaboration\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Merck and Isomorphic Labs Enter Strategic Research Collaboration\",\"datePublished\":\"2026-11-19T11:48:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/merck-and-isomorphic-labs-enter-strategic-research-collaboration\\\/\"},\"wordCount\":1001,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/merck-and-isomorphic-labs-enter-strategic-research-collaboration\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261119112890r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/merck-and-isomorphic-labs-enter-strategic-research-collaboration\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/merck-and-isomorphic-labs-enter-strategic-research-collaboration\\\/\",\"name\":\"Merck and Isomorphic Labs Enter Strategic Research Collaboration - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/merck-and-isomorphic-labs-enter-strategic-research-collaboration\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/merck-and-isomorphic-labs-enter-strategic-research-collaboration\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261119112890r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-11-19T11:48:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/merck-and-isomorphic-labs-enter-strategic-research-collaboration\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/merck-and-isomorphic-labs-enter-strategic-research-collaboration\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/merck-and-isomorphic-labs-enter-strategic-research-collaboration\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261119112890r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261119112890r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/merck-and-isomorphic-labs-enter-strategic-research-collaboration\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck and Isomorphic Labs Enter Strategic Research Collaboration\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck and Isomorphic Labs Enter Strategic Research Collaboration - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/merck-and-isomorphic-labs-enter-strategic-research-collaboration\/","og_locale":"en_US","og_type":"article","og_title":"Merck and Isomorphic Labs Enter Strategic Research Collaboration - Market Newsdesk","og_description":"Merck and Isomorphic Labs Enter Strategic Research Collaboration RAHWAY, N.J.&#8211;(BUSINESS WIRE)&#8211; Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Isomorphic Labs, an AI-first drug design and development company, today announced a research collaboration that brings together Isomorphic Labs\u2019 AI approach to drug discovery with Merck\u2019s rich proprietary data resources and deep discovery experience. The companies will collaborate to discover therapeutic small molecule candidates against an oncology target of strategic importance. Isomorphic Labs will perform in silico predictions and deliver molecular designs, applying its proprietary drug design engine (IsoDDE) incorporating select high-quality proprietary data sets supplied by Merck for the purpose of this collaboration. Merck will be responsible for preclinical and clinical development, as well &hellip; Continue reading \"Merck and Isomorphic Labs Enter Strategic Research Collaboration\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/merck-and-isomorphic-labs-enter-strategic-research-collaboration\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-19T11:48:00+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261119112890r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/merck-and-isomorphic-labs-enter-strategic-research-collaboration\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/merck-and-isomorphic-labs-enter-strategic-research-collaboration\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Merck and Isomorphic Labs Enter Strategic Research Collaboration","datePublished":"2026-11-19T11:48:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/merck-and-isomorphic-labs-enter-strategic-research-collaboration\/"},"wordCount":1001,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/merck-and-isomorphic-labs-enter-strategic-research-collaboration\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261119112890r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/merck-and-isomorphic-labs-enter-strategic-research-collaboration\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/merck-and-isomorphic-labs-enter-strategic-research-collaboration\/","name":"Merck and Isomorphic Labs Enter Strategic Research Collaboration - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/merck-and-isomorphic-labs-enter-strategic-research-collaboration\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/merck-and-isomorphic-labs-enter-strategic-research-collaboration\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261119112890r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-11-19T11:48:00+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/merck-and-isomorphic-labs-enter-strategic-research-collaboration\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/merck-and-isomorphic-labs-enter-strategic-research-collaboration\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/merck-and-isomorphic-labs-enter-strategic-research-collaboration\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261119112890r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261119112890r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/merck-and-isomorphic-labs-enter-strategic-research-collaboration\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Merck and Isomorphic Labs Enter Strategic Research Collaboration"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1022478","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1022478"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1022478\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1022478"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1022478"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1022478"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}